Zava Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which act by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This mechanism helps improve glycemic control without causing significant hypoglycemia. Zava Tablet is indicated as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, for patients inadequately controlled by diet and exercise alone. The recommended dosage is typically 50 mg twice daily, adjusted according to renal function and clinical response. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances, though it is generally well tolerated. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Zava Tablet should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is recommended during treatment. This medication should be used under medical supervision, with attention to lifestyle modifications to optimize therapeutic outcomes in type 2 diabetes management.